Fareeda Y. Coxon

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

David Cunningham, Naureen Starling, Sheela Rao et al. · New England Journal of Medicine · 2008 · 2.3K citations

Medicine, Oncology, Pharmacology +12

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Richard Fox, Daniel H. Palmer, Hassan Malik et al. · The Lancet Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 604 citations · Full text

Public Health, Community Health, Communities Of Practice +14

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox et al. · The Lancet Oncology · 2014 · 374 citations · Full text

Medicine, Oncology, Pharmacotherapy +13